Innovation Pharmaceuticals Inc (IPIX)

[Whoops]

Dr. Jerry I agree with you. Perhaps we are fortunate that Kevetrin has such a strong safety profile to allow it to be dosed so high that some efficacy can be seen even with the quick clearance if not we may have had to rely on elevated p21 levels at conclusion of the trial. Leo mentioned early on in this trial and several times later on that Kevetrin's future is multi-dose. I am excited to see what happens at these high dose levels especially since we had a disappearing spleen lesion and stable disease with the ovarian patient at lower levels.

Looks like we hit a home run with ovarian cancer in this single regime and should get a few more in a multi-dose phase 2 solid tumors.